Best Pharmaceuticals for Children Act
GPTKB entity
Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:administeredBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:amendedBy |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
|
| gptkbp:approvedBy |
2007
2012 2017 |
| gptkbp:citation |
21 U.S.C. § 355a
Public Law 107-109 |
| gptkbp:dateEnacted |
2002
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| gptkbp:focusesOn |
pediatric clinical trials
pediatric drug labeling |
| https://www.w3.org/2000/01/rdf-schema#label |
Best Pharmaceuticals for Children Act
|
| gptkbp:provides |
market exclusivity extension for pediatric studies
|
| gptkbp:purpose |
encourage pediatric drug studies
|
| gptkbp:relatedTo |
gptkb:Pediatric_Research_Equity_Act
|
| gptkbp:signedBy |
gptkb:George_W._Bush
|
| gptkbp:bfsParent |
gptkb:Food_and_Drug_Administration_Amendments_Act_of_2007
|
| gptkbp:bfsLayer |
7
|